These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29748971)

  • 1. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
    Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
    Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
    Kim J; Tomalin L; Lee J; Fitz LJ; Berstein G; Correa-da Rosa J; Garcet S; Lowes MA; Valdez H; Wolk R; Suarez-Farinas M; Krueger JG
    J Invest Dermatol; 2018 Feb; 138(2):273-281. PubMed ID: 28927890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.
    Valenzuela F; Paul C; Mallbris L; Tan H; Papacharalambous J; Valdez H; Mamolo C
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1753-1759. PubMed ID: 27271195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
    Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
    J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
    Zhang J; Tsai TF; Lee MG; Zheng M; Wang G; Jin H; Gu J; Li R; Liu Q; Chen J; Tu C; Qi C; Zhu H; Ports WC; Crook T
    J Dermatol Sci; 2017 Oct; 88(1):36-45. PubMed ID: 28558978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
    Merola JF; Elewski B; Tatulych S; Lan S; Tallman A; Kaur M
    J Am Acad Dermatol; 2017 Jul; 77(1):79-87.e1. PubMed ID: 28396102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C; Harness J; Tan H; Menter A
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.
    Tan H; Valdez H; Griffins CE; Mrowietz U; Tallman A; Wolk R; Gordon K
    J Dermatolog Treat; 2017 Feb; 28(1):3-7. PubMed ID: 27538247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
    Abe M; Nishigori C; Torii H; Ihn H; Ito K; Nagaoka M; Isogawa N; Kawaguchi I; Tomochika Y; Kobayashi M; Tallman AM; Papp KA
    J Dermatol; 2017 Nov; 44(11):1228-1237. PubMed ID: 28714180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
    Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
    Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
    Feldman SR; Thaçi D; Gooderham M; Augustin M; de la Cruz C; Mallbris L; Buonanno M; Tatulych S; Kaur M; Lan S; Valdez H; Mamolo C
    J Am Acad Dermatol; 2016 Dec; 75(6):1162-1170.e3. PubMed ID: 27692733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
    Krueger J; Clark JD; Suárez-Fariñas M; Fuentes-Duculan J; Cueto I; Wang CQ; Tan H; Wolk R; Rottinghaus ST; Whitley MZ; Valdez H; von Schack D; O'Neil SP; Reddy PS; Tatulych S;
    J Allergy Clin Immunol; 2016 Apr; 137(4):1079-1090. PubMed ID: 27059729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
    Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
    BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Quantification of Systemic Inflammatory Proteins Predicts Long-Term Treatment Response to Tofacitinib and Etanercept.
    Tomalin LE; Kim J; Correa da Rosa J; Lee J; Fitz LJ; Berstein G; Valdez H; Wolk R; Krueger JG; Suárez-Fariñas M
    J Invest Dermatol; 2020 May; 140(5):1026-1034. PubMed ID: 31705874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.
    Checchio T; Ahadieh S; Gupta P; Mandema J; Puig L; Wolk R; Valdez H; Tan H; Krishnaswami S; Tallman A; Kaur M; Ito K
    Clin Pharmacol Ther; 2017 Dec; 102(6):1006-1016. PubMed ID: 28480503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
    Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
    Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Human Beta-Defensin-2 Is a Possible Biomarker for Monitoring Response to JAK Inhibitor in Psoriasis Patients.
    Jin T; Sun Z; Chen X; Wang Y; Li R; Ji S; Zhao Y
    Dermatology; 2017; 233(2-3):164-169. PubMed ID: 28654918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis.
    Yu Q; Tong Y; Cui L; Zhang L; Gong Y; Diao H; Gao F; Shi Y
    Int Immunopharmacol; 2019 Aug; 73():442-450. PubMed ID: 31154289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
    Menter MA; Papp KA; Cather J; Leonardi C; Pariser DM; Krueger JG; Wohlrab J; Amaya-Guerra M; Kaszuba A; Nadashkevich O; Tsai TF; Gupta P; Tan H; Valdez H; Mallbris L; Tatulych S
    J Drugs Dermatol; 2016 May; 15(5):568-80. PubMed ID: 27168266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.